George Scangos, CEO of biotechnology company Biogen Idec, will join the board of directors of Agilent Technologies in September.
He will succeed David Lawrence, who is retiring from the board after 13 years as a director, Agilent announced Wednesday.
James Cullen, Agilent chairman, said the company sought Scangos’ knowledge and experience in biotechnology and managing a global pharmaceutical company.
Scangos is a former president and CEO of drug discovery and development company Exelixis and has also served as president of Bayer Biotechnology.
Scangos has also served as non-executive chairman of Anadys Pharmaceuticals between 2005 to 2010, chaired the California Healthcare Institute and was a member of the Global Alliance for TB Drug Development’s board.
He is a member of the National Board of Visitors of the University of California Davis School of Medicine.
